SCHEMBL6315256

SCHEMBL6315256

Cc1ccsc1-c1noc(N)c1C(=O)NC(C)CC(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.41
POLB P06746 1/20 0.36
RAB9A P51151 3/20 0.34
MLYCD O95822 1/20 0.34
TSHR P16473 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33
HPGDS O60760 1/20 0.33
LMNA P02545 2/20 0.33
HSPA5 P11021 1/20 0.32
HSPA2 P54652 1/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
S1PR4 O95977 2/20 0.32
GAA P10253 2/20 0.32
NPC1 O15118 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316220 0.90 TSHR (0.44) ACACBPOLBRAB9ATSHRCYP1A2
SCHEMBL885676 0.89 ACACB (0.37) ACACBPOLBRAB9AMLYCDTSHR
SCHEMBL6318000 0.88 ACACB (0.40) ACACBPOLBRAB9ATSHRCYP1A2
SCHEMBL6323085 0.88 RAB9A (0.40) ACACBPOLBRAB9ATSHRCYP1A2
SCHEMBL6317729 0.87 HPGD (0.43) ACACBPOLBRAB9ATSHRLMNA
SCHEMBL6324723 0.85 POLB (0.36) ACACBPOLBRAB9ACYP1A2CYP2C9
SCHEMBL6314609 0.85 TAS1R3 (0.38) ACACBPOLBRAB9AMLYCDTSHR
SCHEMBL6322906 0.84 GAA (0.42) POLBRAB9ALMNAALDH1A1MEN1
SCHEMBL6315855 0.84 POLB (0.38) ACACBPOLBRAB9ATSHRCYP1A2
SCHEMBL6321245 0.84 HPGD (0.52) POLBTSHRLMNAALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 ACACB 1255/4885POLB 872/4885RAB9A 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.